Proprietary Genome Editing Platforms

September 14, 2018

Companies covered: Oxford BioMedica plc (LON:OXB), miRagen Therapeutics, Inc. (NASDAQ:MGEN), IDEXX Laboratories, Inc. (NASDAQ:IDXX), The Medicines Company (NASDAQ:MDCO), Amgen Inc. (NASDAQ:AMGN), Biogen Inc. (NASDAQ:BIIB), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Cooper Companies, Inc. (The) (NYSE:COO), Johnson & Johnson (NYSE:JNJ), Marathon Petroleum Corporation (NYSE:MPC), Pioneer Natural Resources Company (NYSE:PXD), Takeda Pharmaceutical Co. Ltd. (ADR) (OTCMKTS:TKPYY), Andeavor (NYSE:ANDV), Spark Therapeutics, Inc. (NASDAQ:ONCE), Audentes Therapeutics (NASDAQ:BOLD), Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), Zogenix, Inc. (NASDAQ:ZGNX), Novartis AG (NYSE:NVS), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Selecta Biosciences Inc (NASDAQ:SELB), ViewRay Inc. (NASDAQ:VRAY), Novocure Ltd. (NASDAQ:NVCR), Nightstar Therapeutics PLC (NASDAQ:NITE), Dentsply Sirona (NASDAQ:XRAY), Gilead Sciences, Inc. (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG), Qiagen N.V. (NASDAQ:QGEN), Cancer Genetics, Inc. (NASDAQ:CGIX), Acorda Therapeutics, Inc. (NASDAQ:ACOR), Sorrento Therapeutics, Inc. (NASDAQ:SRNE), Merck & Company, Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), Bausch Health Companies (NYSE:BHC), Abeona Therapeutics (NASDAQ:ABEO), Acer Therapeutics (NASDAQ:ACER), HTG Molecular Diagnostics (NASDAQ:HTGM), Intec Pharma (NASDAQ:NTEC), Fate Therapeutics, Inc. (NASDAQ:FATE), bluebird bio, Inc. (NASDAQ:BLUE), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Unum Therapeutics (NASDAQ:UMRX), Blueprint Medicines Corp. (NASDAQ:BPMC), AVROBIO (NASDAQ:AVRO), Voyager Therapeutics (NASDAQ:VYGR), Fortress Biotech, Inc. (NASDAQ:FBIO), Interpace Diagnostics Group, Inc. (NASDAQ:IDXG), GenSight Biologics SA (EPA:SIGHT), Mustang Bio, Inc. (NASDAQ:MBIO)

Buy ($175)